Rohto Pharmaceutical Co.,Ltd.

TSE:4527 주식 보고서

시가총액: JP¥626.1b

Rohto PharmaceuticalLtd 관리

관리 기준 확인 3/4

Rohto PharmaceuticalLtd CEO는 Yamada Kunio, Jun2009 에 임명되었습니다 의 임기는 15.42 년입니다. 총 연간 보상은 ¥ 212.00M, 89.6% 로 구성됩니다. 89.6% 급여 및 10.4% 보너스(회사 주식 및 옵션 포함). 는 ¥ 10.92B 가치에 해당하는 회사 주식의 1.74% 직접 소유합니다. 10.92B. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 5.4 년입니다.

주요 정보

Yamada Kunio

최고 경영자

JP¥212.0m

총 보상

CEO 급여 비율89.6%
CEO 임기15.4yrs
CEO 소유권1.7%
경영진 평균 재임 기간2.7yrs
이사회 평균 재임 기간5.4yrs

최근 관리 업데이트

Recent updates

Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 15
Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Rohto Pharmaceutical Co.,Ltd. (TSE:4527) Shares Could Be 25% Below Their Intrinsic Value Estimate

Nov 07
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) Shares Could Be 25% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well

Oct 20
These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well

Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price

Oct 06
Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Sep 22
Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Aug 25
Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Aug 11
Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11
Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Jun 23
Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Jun 10
Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

May 14
Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03
These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21
Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07
Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26
Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

CEO 보상 분석

Yamada Kunio 의 보수는 Rohto PharmaceuticalLtd 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

JP¥27b

Jun 30 2024n/an/a

JP¥30b

Mar 31 2024JP¥212mJP¥190m

JP¥31b

Dec 31 2023n/an/a

JP¥31b

Sep 30 2023n/an/a

JP¥30b

Jun 30 2023n/an/a

JP¥28b

Mar 31 2023JP¥205mJP¥183m

JP¥26b

Dec 31 2022n/an/a

JP¥26b

Sep 30 2022n/an/a

JP¥23b

Jun 30 2022n/an/a

JP¥23b

Mar 31 2022JP¥196mJP¥178m

JP¥21b

Dec 31 2021n/an/a

JP¥23b

Sep 30 2021n/an/a

JP¥21b

Jun 30 2021n/an/a

JP¥20b

Mar 31 2021JP¥185mJP¥176m

JP¥17b

Dec 31 2020n/an/a

JP¥14b

Sep 30 2020n/an/a

JP¥14b

Jun 30 2020n/an/a

JP¥15b

Mar 31 2020JP¥192mJP¥179m

JP¥15b

Dec 31 2019n/an/a

JP¥11b

Sep 30 2019n/an/a

JP¥10b

Jun 30 2019n/an/a

JP¥9b

Mar 31 2019JP¥181mJP¥173m

JP¥10b

보상 대 시장: Yamada 의 총 보상 ($USD 1.37M )은 JP 시장( $USD 926.78K ).

보상과 수익: Yamada 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Yamada Kunio (68 yo)

15.4yrs

테뉴어

JP¥212,000,000

보상

Mr. Yamada Kunio had been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009 until 2019. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharma...

리더십 팀

이름위치테뉴어보상소유권
Yamada Kunio
Chairman of the Board & CEO15.4yrsJP¥212.00m1.74%
¥ 10.9b
Masashi Sugimoto
President5.4yrs데이터 없음0.0075%
¥ 46.6m
Saito Masaya
EVP, CFO & Director2.7yrs데이터 없음0.021%
¥ 129.0m
Shinichi Kunisaki
EVP, CTO & Director2.7yrs데이터 없음0.018%
¥ 112.5m
Hideto Kamimura
Senior Executive Officer and General Manager of Marketing Division no data데이터 없음0.0053%
¥ 32.9m
Yasunori Kawasaki
CHRO & Director1.4yrs데이터 없음데이터 없음
Hidetoshi Segi
MD, Chief Strategy Officer & Director2.7yrs데이터 없음0.0039%
¥ 24.7m

2.7yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 관리: 4527 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Yamada Kunio
Chairman of the Board & CEO25.4yrsJP¥212.00m1.74%
¥ 10.9b
Masashi Sugimoto
President5.4yrs데이터 없음0.0075%
¥ 46.6m
Saito Masaya
EVP, CFO & Director13.4yrs데이터 없음0.021%
¥ 129.0m
Shinichi Kunisaki
EVP, CTO & Director14.4yrs데이터 없음0.018%
¥ 112.5m
Yasunori Kawasaki
CHRO & Director1.4yrs데이터 없음데이터 없음
Hidetoshi Segi
MD, Chief Strategy Officer & Director6.4yrs데이터 없음0.0039%
¥ 24.7m
Kimura Masanori
Standing Corporate Auditor8.4yrs데이터 없음0.027%
¥ 167.4m
Akie Iriyama
Independent Outside Director5.4yrs데이터 없음데이터 없음
Haruka Mera
Independent Outside Director4.4yrs데이터 없음데이터 없음
Tatsuo Uemura
Independent Outside Director2.4yrs데이터 없음0.00044%
¥ 2.8m
Eriko Hayashi
Independent Outside director2.4yrs데이터 없음데이터 없음
Maiko Katadae
Independent Outside Directorless than a year데이터 없음데이터 없음

5.4yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: 4527 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.